Watson N R, Studd J W, Savvas M, Garnett T, Baber R J
PMT Clinic, Dulwich Hospital, London.
Lancet. 1989 Sep 23;2(8665):730-2. doi: 10.1016/s0140-6736(89)90784-8.
40 patients with premenstrual symptoms were randomly allocated to receive placebo patches or active treatment with transdermal oestradiol patches (2 x 100 micrograms) to suppress ovulation. Norethisterone 5 mg was given in each group from day 19-26 of the cycle to ensure a regular withdrawal bleed. Treatment was for 6 months with crossover at 3 months. Patients completed the Moos menstrual distress questionnaire (MDQ) and the premenstrual distress questionnaire (PDQ) daily throughout the study. 5 patients withdrew, 4 because of skin reactions and 1 because of considerable improvement with initial (active) treatment. After 3 months, both groups showed improvement in MDQ and PDQ scores. In general, between 3 and 6 months, patients who switched from active treatment to placebo had deteriorating scores while patients who switched from placebo to active treatment maintained or improved upon their initial gains. Significant improvements occurred after changing to active treatment in five of six negative MDQ symptom clusters and in six of ten PDQ symptoms.
40名有经前症状的患者被随机分配接受安慰剂贴片或经皮雌二醇贴片（2×100微克）的积极治疗以抑制排卵。每组在月经周期的第19至26天给予5毫克炔诺酮以确保有规律的撤退性出血。治疗为期6个月，在3个月时进行交叉。在整个研究过程中，患者每天完成穆氏月经困扰问卷（MDQ）和经前困扰问卷（PDQ）。5名患者退出，4名是因为皮肤反应，1名是因为初始（积极）治疗后有显著改善。3个月后，两组的MDQ和PDQ评分均有所改善。总体而言，在3至6个月期间，从积极治疗转为安慰剂治疗的患者评分恶化，而从安慰剂转为积极治疗的患者保持或改善了其初始的改善情况。在六个MDQ阴性症状群中的五个以及十个PDQ症状中的六个中，转为积极治疗后出现了显著改善。
